You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Novel therapeutic for hematopoietic stem cell regeneration in bone marrow post my
SBC: Minerva Biotechnologies Corporation Topic: NIAIDDESCRIPTION (provided by applicant): The purpose of this study is to establish in vivo proof of principle for a human therapeutic for hematopoietic stem cell regeneration in the bone marrow after myeloablation from radiation. Blood stem cells are the mostsusceptible to the effects of radiation and the most lethal. We have already demonstrated proof of principle for our therapeutic in vitro. If suc ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Antibody-Membrane Switch (AMS) technology for optimized antibody engineering
SBC: Panorama Research Incorporated Topic: NIAIDAbstract Generation of high productivity cell lines remains a major bottleneck in therapeutic antibody engineering. To address this need, we have developed a proprietary Antibody-Membrane Switch (AMS) technology that facilitates rapid cloning of cell lines for commercial production of antibodies. This technology streamlines identification of high-productivity clones, shaving at least 6-8 months o ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Transcriptional silencing of latent HIV infection- a novel small molecule class
SBC: SIRENAS MARINE DISCOVERY, LLC Topic: NIAIDDESCRIPTION: Though highly effective in changing the course of the global HIV epidemic, current Antiretroviral Therapy (ART) fails to eradicate the infection completely. This has led to the emergence of drug-resistant mutant strains, the phenomenon of latent disease and a number of adherence and toxicity issues associate with long-term therapy. Novel compounds that inhibit transcription from integ ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Engineering of a Novel CDN Nanoparticle Platform
SBC: MOLECULAR EXPRESS, INC Topic: NIAIDDESCRIPTION (provided by applicant): For many years, the use of protein and peptide antigens to induce specific immune responses has been an area of intense effort with the goal of developing improved vaccines. In principle, this approach is attractive because it has the potential to provide immunological specificity, tighter control of manufacturing processes, and elimination of most of the secon ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Algae-expressed colostrum protein as prophylaxis for enterotoxigenic E. coli
SBC: TRITON ALGAE INNOVATIONS, INC. Topic: NIAIDDESCRIPTION (provided by applicant): Enterotoxigenic E. coli (ETEC) is the leading cause of diarrheal disease among children less than three years of age in developing countries and in travelers to these areas, with over 200 million cases annually, and 380,000 associated deaths. ETEC is transmitted by food or water contaminated with feces, and illness is characterized by profuse watery diarrhea la ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Discovering a Targeted Inositol Phosphorylceramide Synthase Inhibitor to Improve
SBC: Amplyx Pharmaceuticals, Inc. Topic: NIAIDDESCRIPTION (provided by applicant): Cryptococcal meningitis (CM) is the AIDS-defining illness for 60-70% of HIV positive individuals with an estimated worldwide occurrence of 1 million cases annually. CM is invariably fatal if left untreated, In sub-Saharan Africa alone, CM causes over 500,000 annual deaths among HIV positive patients compared with 350,000 annual deaths for tuberculosis in the ge ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of the RXR agonist IRX4204 to treat Multiple Sclerosis and other Immu
SBC: IO THERAPEUTICS, INC. Topic: NIAIDDESCRIPTION (provided by applicant): Io Therapeutics is developing a novel agonist for the Retinoid X Receptors (RXR), IRX4204, to treat multiple sclerosis (MS) and other autoimmune diseases. RXR is a key nuclear receptor involved in inflammation. It has arole in regulating immunity through the enhancement of Treg activities and suppression of inflammatory Th17 activities. Because of the importanc ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Elastase Inhibition as a Novel Therapeutic Approach for Neuromyelitis Optica
SBC: ANVIL BIOSCIENCES LLC Topic: NIAIDDESCRIPTION (provided by applicant): Neuromyelitis Optica (NMO) is a rare autoimmune inflammatory disease that affects the spinal cord and optical nerves leading to limb paralysis and loss of vision. Despite advances in the understanding of underlying disease mechanisms and patient diagnostic criteria there is a lack of treatment options. A specific cellular component of NMO disease was found to ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A MERS-CoV Receptor Decoy
SBC: PLANET BIOTECHNOLOGY, INC. Topic: NIAIDDESCRIPTION (provided by applicant): Middle East respiratory syndrome coronavirus (MERS-CoV) is newly emerging human health threat with a more than 40% case fatality rate. The cell surface protein dipeptidyl peptidase 4 (DPP4) is used by MERS-CoV to enterand infect cells. Soluble recombinant human DPP4 binds the MERS-CoV spike (S) glycoprotein and inhibits MERS-CoV infection of VERO cells, but the ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A Cell-Penetrating Anthrax Antitoxin
SBC: PLANET BIOTECHNOLOGY, INC. Topic: NIAIDDESCRIPTION (provided by applicant): The goal of this research is to develop an economical, safe, effective therapy to reverse the activity of the catalytic component, LF, of the Bacillus anthracis toxin (lethal toxin), within the cytoplasm of the intoxicated cell. Success in achieving this goal will lead to better outcomes than currently seen with antibiotics or antitoxins like raxibacumab or PB ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health